熱門資訊> 正文
PMV Pharma IPO定价为5000万美元，每股1.21美元
2026-09-01 16:47
- PMV Pharmaceuticals (PMVP) priced an oversubscribed public offering expected to raise about $50.8M in gross proceeds.
- The offering includes 22.055M shares of common stock and pre-funded warrants to purchase up to 19.9M shares, along with warrants to purchase an aggregate of 41.955M shares of common stock.
- The combined offering price is $1.21 per share and accompanying warrant. Pre-funded warrants are priced at $1.20999 each, with an exercise price of $0.00001 per share.
- PMV Pharma is a precision oncology company developing small-molecule therapies targeting p53. The company said TP53 mutations are found in approximately half of all cancers.
- The offering is expected to close on or about September 2.
More on PMV Pharmaceuticals
- Seeking Alpha’s Quant Rating on PMV Pharmaceuticals
- Historical earnings data for PMV Pharmaceuticals
- Financial information for PMV Pharmaceuticals
推薦文章
衝刺人類史上最大IPO！Anthropic營收五季狂飆30倍，數千億美元算力盛宴開啟，誰在悶聲賺大錢？
美股前瞻 | 伊朗釋放和平信號！期指轉漲油價回落；SK海力士盤前升逾3%，將於盤后放榜！
10月27日外盤頭條：巴西股市暴跌 特朗普質疑盧拉勝選 蘋果承認少量iPhoneDuo內屏裂紋 Anthropic遞表
iPhone Duo開售不久即被曝內屏出現裂紋 蘋果承認少量設備受影響
從伊朗戰爭、政府腐敗到人工智能 美國中期選舉九大議題角力激烈
馬斯克警示新雲廠商：它們將迎來 「孔雀魚式消亡」
Anthropic公開遞交納斯達克IPO申請：上半年淨虧損807億美元
期權交易指南 | 存儲股被錯殺？閃迪財報日將迎13%大波動；中金喊話增配黃金對衝AI風險
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
